KR102247795B9 - 급성 골수성 백혈병 또는 전이성 유방암의 예방 또는 치료용 약제학적 조성물 - Google Patents
급성 골수성 백혈병 또는 전이성 유방암의 예방 또는 치료용 약제학적 조성물Info
- Publication number
- KR102247795B9 KR102247795B9 KR1020180131294A KR20180131294A KR102247795B9 KR 102247795 B9 KR102247795 B9 KR 102247795B9 KR 1020180131294 A KR1020180131294 A KR 1020180131294A KR 20180131294 A KR20180131294 A KR 20180131294A KR 102247795 B9 KR102247795 B9 KR 102247795B9
- Authority
- KR
- South Korea
- Prior art keywords
- inhibiting
- treating
- composition
- breast cancer
- myeloid leukemia
- Prior art date
Links
- 208000031261 Acute myeloid leukaemia Diseases 0.000 title 1
- 206010055113 Breast cancer metastatic Diseases 0.000 title 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170144142 | 2017-10-31 | ||
KR20170144142 | 2017-10-31 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020210052728A Division KR20210047850A (ko) | 2021-04-23 | 2021-04-23 | 급성 골수성 백혈병 또는 전이성 유방암의 예방 또는 치료용 약제학적 조성물 |
Publications (3)
Publication Number | Publication Date |
---|---|
KR20190049584A KR20190049584A (ko) | 2019-05-09 |
KR102247795B1 KR102247795B1 (ko) | 2021-05-04 |
KR102247795B9 true KR102247795B9 (ko) | 2023-04-12 |
Family
ID=66333236
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020180131294A KR102247795B1 (ko) | 2017-10-31 | 2018-10-30 | 급성 골수성 백혈병 또는 전이성 유방암의 예방 또는 치료용 약제학적 조성물 |
Country Status (12)
Country | Link |
---|---|
US (1) | US11370779B2 (ko) |
EP (1) | EP3705474A4 (ko) |
JP (1) | JP7005779B2 (ko) |
KR (1) | KR102247795B1 (ko) |
CN (1) | CN111542513A (ko) |
AU (1) | AU2018358582B2 (ko) |
BR (1) | BR112020008499A2 (ko) |
CA (1) | CA3080900C (ko) |
MX (1) | MX2020004374A (ko) |
PH (1) | PH12020550491A1 (ko) |
RU (1) | RU2763346C2 (ko) |
WO (1) | WO2019088677A1 (ko) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110305056A (zh) * | 2019-05-22 | 2019-10-08 | 西北大学 | 靛玉红新衍生物及其药用用途 |
WO2021090172A1 (en) * | 2019-11-04 | 2021-05-14 | Ck Biotechnology Co. | Compositions and methods for suppressing and/or treating neurodegenerative diseases and/or a clinical condition thereof |
KR102443617B1 (ko) * | 2019-12-06 | 2022-09-16 | 광주과학기술원 | 근감소증 또는 근위축증의 예방 또는 치료용 약제학적 조성물 |
WO2021112626A1 (ko) * | 2019-12-06 | 2021-06-10 | 주식회사 펠레메드 | 신규한 인디루빈 유도체 및 이의 용도 |
KR102325607B1 (ko) | 2020-02-20 | 2021-11-12 | 한국과학기술원 | Ash1l 히스톤 메틸화 효소 활성을 억제하는 벤조퓨란-피라졸 유도체 화합물을 포함하는 백혈병의 예방 또는 치료용 조성물 |
KR20210106155A (ko) | 2020-02-20 | 2021-08-30 | 한국과학기술원 | Ash1l 히스톤 메틸화 효소 활성을 억제하는 페닐카르보노히드라조노일 디시아나이드 유도체 화합물을 포함하는 백혈병의 예방 또는 치료용 조성물 |
KR102278176B1 (ko) | 2020-02-20 | 2021-07-16 | 한국과학기술원 | Ash1l 히스톤 메틸화 효소 활성을 억제하는 벤조디옥솔 유도체 화합물을 포함하는 백혈병의 예방 또는 치료용 조성물 |
US20220079934A1 (en) * | 2020-09-17 | 2022-03-17 | Arog Pharmaceuticals, Inc. | Crenolanib for treating pain |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SK14272001A3 (sk) * | 1999-04-12 | 2002-05-09 | Gerhard Eisenbrand | Indigoidné bisindolové deriváty |
FR2850652B1 (fr) * | 2003-01-31 | 2008-05-30 | Aventis Pharma Sa | Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases |
KR100588803B1 (ko) * | 2004-01-27 | 2006-06-12 | 학교법인조선대학교 | 암세포주에 항암활성을 지닌 인디루빈 유도체 |
WO2007099402A2 (en) | 2005-12-23 | 2007-09-07 | Centre National De La Recherche Scientifique (Cnrs) | New 3’-, 7-substituted indirubins and their applications |
ATE529402T1 (de) | 2008-08-01 | 2011-11-15 | Centre Nat Rech Scient | 3',6-substituierte indirubine und ihre biologischen anwendungen |
KR101180030B1 (ko) * | 2010-02-05 | 2012-09-05 | 광주과학기술원 | 사이클린-의존적 키나제 저해제로서 항암 활성을 지닌 인디루빈-3'-옥심 유도체 |
EP2518139A1 (en) * | 2011-04-27 | 2012-10-31 | Universitätsklinikum Jena | Use of indirubin derivatives for producing pluripotent stem cells |
US10435367B2 (en) * | 2013-03-14 | 2019-10-08 | City Of Hope | Indirubin derivatives, and uses thereof |
EP2827869A4 (en) * | 2012-03-23 | 2015-09-23 | Dennis Brown | COMPOSITIONS AND METHODS FOR IMPROVING THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ITS ANALOGUES INCLUDING MESOINDIGO |
BR112015023383A2 (pt) * | 2013-03-14 | 2017-07-18 | Hope City | compostocomposição farmacêutica; e método de modulação |
US20150259288A1 (en) * | 2014-03-14 | 2015-09-17 | City Of Hope | 5-bromo-indirubins |
-
2018
- 2018-10-30 EP EP18873750.6A patent/EP3705474A4/en active Pending
- 2018-10-30 KR KR1020180131294A patent/KR102247795B1/ko active IP Right Grant
- 2018-10-30 CA CA3080900A patent/CA3080900C/en active Active
- 2018-10-30 CN CN201880084849.8A patent/CN111542513A/zh active Pending
- 2018-10-30 JP JP2020543443A patent/JP7005779B2/ja active Active
- 2018-10-30 BR BR112020008499-9A patent/BR112020008499A2/pt not_active IP Right Cessation
- 2018-10-30 MX MX2020004374A patent/MX2020004374A/es unknown
- 2018-10-30 RU RU2020115581A patent/RU2763346C2/ru active
- 2018-10-30 AU AU2018358582A patent/AU2018358582B2/en active Active
- 2018-10-30 WO PCT/KR2018/013051 patent/WO2019088677A1/ko unknown
-
2020
- 2020-04-24 PH PH12020550491A patent/PH12020550491A1/en unknown
- 2020-04-30 US US16/862,923 patent/US11370779B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
PH12020550491A1 (en) | 2021-01-11 |
JP7005779B2 (ja) | 2022-02-10 |
KR20190049584A (ko) | 2019-05-09 |
EP3705474A1 (en) | 2020-09-09 |
EP3705474A4 (en) | 2021-06-09 |
MX2020004374A (es) | 2020-11-11 |
BR112020008499A2 (pt) | 2020-10-20 |
RU2763346C2 (ru) | 2021-12-28 |
WO2019088677A1 (ko) | 2019-05-09 |
CA3080900C (en) | 2022-10-25 |
JP2021501208A (ja) | 2021-01-14 |
US20200270229A1 (en) | 2020-08-27 |
AU2018358582A1 (en) | 2020-05-07 |
RU2020115581A3 (ko) | 2021-12-02 |
RU2020115581A (ru) | 2021-12-02 |
CA3080900A1 (en) | 2019-05-09 |
CN111542513A (zh) | 2020-08-14 |
KR102247795B1 (ko) | 2021-05-04 |
US11370779B2 (en) | 2022-06-28 |
AU2018358582B2 (en) | 2021-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102247795B9 (ko) | 급성 골수성 백혈병 또는 전이성 유방암의 예방 또는 치료용 약제학적 조성물 | |
PL3431105T3 (pl) | Kompozycja lecznicza do leczenia raka | |
IL260444B (en) | Anti-her2 combinations for cancer treatment | |
RS63561B1 (sr) | Kompozicija za lečenje raka | |
EP3134115A4 (en) | Methods and compositions for treating metastatic breast cancer and other cancers in the brain | |
RS63311B1 (sr) | Ar+ metode lečenja raka dojke | |
GB201709677D0 (en) | Treatment for acute myeloid leukaemia | |
GB201709405D0 (en) | Compounds for treating ovarian cancer | |
KR102269666B9 (ko) | 전이성 난소암, 자궁내막암 또는 유방암의 예방 또는 치료용 조성물 | |
IL265938B (en) | Zofoxifene treatment for +er breast cancer | |
SG11202010528XA (en) | Combinations for treating cancer | |
IL283337A (en) | Methods for treating whsc1-overexpressing cancers by inhibiting setd2 | |
ZA201900939B (en) | Combination treatment for hematological cancers | |
PL3296294T3 (pl) | Związek do leczenia lub zapobiegania nowotworowi piersi | |
IL288135A (en) | Compounds containing bisfluoroalkyl-1,4-benzodiazepines for the treatment of breast cancer characterized by Notch activation | |
IL269769B (en) | Mixtures, composition and their use for cancer treatment | |
GB201909468D0 (en) | Compounds for treating cancer | |
IL261160B (en) | Methods of treating acute myeloid leukemia | |
SG11202003967PA (en) | Compositions comprising alpha-polyglutamic acid-zinc for treating cancer | |
IL282692A (en) | Compounds derived from madrasin, a preparation and their uses for the treatment of cancer | |
IL272379A (en) | Methods for treating cancer using SETDS inhibition | |
PL3630754T3 (pl) | Związki izoindolinoacetylenowe do leczenia nowotworu | |
PL3319638T3 (pl) | Kompozycja zawierająca cyneol do leczenia chorób nowotworowych i/lub raków | |
IL282228A (en) | A combination solution for the treatment of chemotherapy-resistant cancer | |
PT3813832T (pt) | Compostos para utilização na prevenção ou tratamento de cancro |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
X091 | Application refused [patent] | ||
AMND | Amendment | ||
X701 | Decision to grant (after re-examination) | ||
GRNT | Written decision to grant | ||
G170 | Re-publication after modification of scope of protection [patent] |